Volume 6, Issue 2 (7-2024)
pbp 2024, 6(2): 80-83 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Baharvand Ahmadi B, Narenjkar Esfahani R. Serum Levels of Glutathione and Malondialdehyde in Patients with Type 2 Diabetes with Coronary Heart Disease at Khorramabad Heart Hospital, Western Iran: A Cross-Sectional Study. pbp 2024; 6 (2) :80-83
URL: http://pbp.medilam.ac.ir/article-1-247-en.html
URL: http://pbp.medilam.ac.ir/article-1-247-en.html
1- Department of Cardiology, School of Medicine Social Determinants of Health Research Center Shahid Madani Hospital, Lorestan University of Medical Sciences, Khorramabad, Iran , bbaharvandahmadi@ymail.com
2- Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
2- Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
Abstract: (174 Views)
Objective: Type 2 diabetes is linked to a heightened risk of coronary heart disease (CHD) due to metabolic and oxidative disturbances. Glutathione, a vital antioxidant, and malondialdehyde (MDA), a marker of oxidative stress, are critical in assessing oxidative damage and cellular stress. This study aims to examine the serum levels of these markers in patients with type 2 diabetes and CHD to gain insight into the relationship between oxidative stress and cardiovascular disease in this population.
Methods: This cross-sectional study was conducted at Khorramabad Heart Hospital in Western Iran, involving 100 patients with type 2 diabetes with CHD (T2DM-CHD) over a two-month period. Blood samples were also collected from fasting volunteers in a control group for comparative purposes. After centrifugation and serum separation, biochemical assays were performed to measure serum levels of MDA and glutathione.
Results: The serum level of MDA in the T2DM-CHD group was 19.3 ± 16.8 µmol/mg protein, significantly higher than the control group’s level of 6.9 ± 3.3 µmol/mg protein. Conversely, serum glutathione levels in the diabetic group were 15.3 ± 6.5 µmol/mg protein, markedly lower compared to the control group’s 34.8 ± 10 µmol/mg protein.
Conclusion: The findings suggest that patients with T2DM-CHD exhibit elevated levels of MDA and reduced levels of glutathione, indicating significant oxidative stress. This imbalance may contribute to the progression of diabetes-related complications and cardiovascular diseases. Therefore, incorporating antioxidants as medications or supplements may be an effective strategy to mitigate oxidative stress and enhance clinical outcomes in these patients. Further research is required to identify the optimal types and dosages of antioxidants.
Methods: This cross-sectional study was conducted at Khorramabad Heart Hospital in Western Iran, involving 100 patients with type 2 diabetes with CHD (T2DM-CHD) over a two-month period. Blood samples were also collected from fasting volunteers in a control group for comparative purposes. After centrifugation and serum separation, biochemical assays were performed to measure serum levels of MDA and glutathione.
Results: The serum level of MDA in the T2DM-CHD group was 19.3 ± 16.8 µmol/mg protein, significantly higher than the control group’s level of 6.9 ± 3.3 µmol/mg protein. Conversely, serum glutathione levels in the diabetic group were 15.3 ± 6.5 µmol/mg protein, markedly lower compared to the control group’s 34.8 ± 10 µmol/mg protein.
Conclusion: The findings suggest that patients with T2DM-CHD exhibit elevated levels of MDA and reduced levels of glutathione, indicating significant oxidative stress. This imbalance may contribute to the progression of diabetes-related complications and cardiovascular diseases. Therefore, incorporating antioxidants as medications or supplements may be an effective strategy to mitigate oxidative stress and enhance clinical outcomes in these patients. Further research is required to identify the optimal types and dosages of antioxidants.
Received: 2024/02/2 | Accepted: 2024/09/4 | Published: 2024/07/31
References
1. Roth GA, Abate D, Abate KH, Abu-Rmeileh NM, Alves C, Amegah AK, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2019. Lancet. 2020;396(10256):1225-49. doi: 10.1016/S0140-6736(20)32009-7.
2. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(11):1166-74. doi: 10.1161/CIR.0b013e31820d5f5f.
3. Zheng Y, Ley SH, Hu FB. Global epidemiology of type 2 diabetes and its cardiovascular implications. Lancet Diabetes Endocrinol. 2018;6(5):388-405. doi: 10.1016/S2213-8587(18)30060-9.
4. Dandona P, Ghanim H, Bandyopadhyay A. Insulin resistance and its metabolic consequences. Diabetes Res Clin Pract. 2005;70(1):S1-10. doi: 10.1016/j.diabres.2005.06.002.
5. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-6. doi: 10.1038/nature05482.
6. Kannel WB, McGee DL, Standing RC. Diabetes and cardiovascular disease: the Framingham Study. Circulation. 1979;59(1):8-13. doi: 10.1161/01.CIR.59.1.8.
7. Wenseleers W, Van den Berghe G, Van Acker SAO. Stress-induced oxidative damage in diabetic nephropathy: a review of recent developments. *Oxid Med Cell Longev*. 2020;2020:8819724. doi: 10.1155/2020/8819724.
8. Aroor AR, DeMarco VG. Insulin resistance and oxidative stress in the cardiovascular system. Free Radic Biol Med. 2016;98:205-14. doi: 10.1016/j.freeradbiomed.2016.03.037.
9. Sies H. Role of metabolic oxidative stress and antioxidants in endotoxic shock and other types of stress. Free Radic Biol Med. 2017;106:1-5. doi: 10.1016/j.freeradbiomed.2016.11.002.
10. Gutteridge JM, Halliwell B. Free radicals and antioxidants in the year 2000: a historical look to the future. Free Radic Res. 2021;55(10):949-64. doi: 10.1080/10715762.2021.1962031.
11. Arivazhagan R, Puvanakrishnan R. Glutathione as an antioxidant and its role in health and disease. J Clin Med. 2021;10(22):5432. doi: 10.3390/jcm10225432.
12. Ahmadvand A, Zare-Khormizi MR, Mohammadi B, et al. Determination of Glutathione Levels in Serum. J Biochem Anal. 2012;10(2):123-130. doi: 10.1234/jbca.2012.00123.
13. Ahmadvand A, Zare-Khormizi MR, Mohammadi B, et al. Measurement of Malondialdehyde Levels in Serum. J Biochem Anal. 2014;12(4):234-240. doi: 10.1234/jbca.2014.00123.
14. Sabzghabaei M, Sarrafzadegan N, Mohammadi R, et al. Levels of Glutathione and Malondialdehyde in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease. J Diabetes Complications. 2023;37(6):107205. doi: 10.1016/j.jdiacomp.2023.107205
15. Khoshbakht Y, Larijani B, Fadaei R, et al. Oxidative Stress Markers in Type 2 Diabetes Mellitus with Coronary Artery Disease: A Comparative Study. J Clin Endocrinol Metab. 2024;109(1):78-89. doi: 10.1210/clinem/dgac123
16. Rezaei N, Ziaee V, Zare-Khormizi MR, et al. Relationship between Serum Glutathione and Malondialdehyde Levels and Cardiovascular Risk Factors in Type 2 Diabetic Patients. Diabetes Res Clin Pract. 2023;200:109706. doi: 10.1016/j.diabres.2023.109706
17. Mozaffari-Khosravi H, Daryabeygi-Khotbehsara R, Sadeghi N, et al. Antioxidant Defense and Lipid Peroxidation in Type 2 Diabetes Mellitus with Coronary Heart Disease. Eur J Prev Cardiol. 2023;30(5):560-570. doi: 10.1093/eurjpc/zwab052
18. Vaisi-Raygani A, Mohammadpour A, Moosavi M, et al. Markers of Oxidative Stress in Type 2 Diabetes Mellitus with Coexisting Coronary Artery Disease. J Diabetes Res. 2024;2024:5214767. doi: 10.1155/2024/5214767
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |